• Canbridge launched registration work to expand Gaucher drug Gaurunning into a key North African market, starting commercial launch preparations.
• Move marks the first step in its international rollout for the global Gaucher disease market, targeting unmet demand in the region.
• Gaurunning won China marketing clearance on May 15, 2025 for Type I and III Gaucher patients aged 12+; a trial aims to add ages 2-11.
• No Gaurunning sales revenue has been generated from North Africa so far; market entry remains subject to local regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12261943), on July 30, 2026, and is solely responsible for the information contained therein.